AbbVie (NYSE:ABBV) announced Monday a setback for a Phase 3 trial designed to test its Roche (OTCQX:RHHBF)-partnered leukemia ...

A combination of acalabrutinib and venetoclax showed better results with the addition of obinutuzumab, whereas mixed findings ...

A UK trial has revealed a chemotherapy-free approach to treating chronic lymphocytic leukaemia (CLL), marking a significant milestone in cancer management.

During a live event, Danielle M. Brander, MD, discussed use of zanubrutinib in high-risk chronic lymphocytic leukemia.

AbbVie (NYSE: ABBV) announced the global Phase 3 VERONA trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) ...

During a live event, John S. Renshaw, MD, and other oncologists discussed various trials of novel regimens for patients with ...

Statin use was significantly associated with improved survival outcomes in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), regardless of treatment type or ...

The debate continues over the potential of measurable residual disease to transform research and clinical care in hematology.

Schrödinger (SDGR) stock fell after Phase 1 trial data for SGR-1505 its experimental drug for B-cell malignancies. Read more ...

Researchers observed inequities in receipt of first-line preferred therapies among a cohort of patients with chronic ...

Glenmark shares on Monday ended 0.68% up at ₹1,600.85 apiece on BSE. New Delhi: Glenmark Pharmaceuticals on Monday said it ...